0001213900-24-023494.txt : 20240416 0001213900-24-023494.hdr.sgml : 20240416 20240318161043 ACCESSION NUMBER: 0001213900-24-023494 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AKANDA CORP. CENTRAL INDEX KEY: 0001888014 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1A, 1B LEAROYD ROAD CITY: NEW ROMNEY STATE: X0 ZIP: TN28 8XU BUSINESS PHONE: 442034889514 MAIL ADDRESS: STREET 1: 77 KING STREET WEST, SUITE 400 STREET 2: C/O DENTONS CANADA LLP CITY: TORONTO STATE: A6 ZIP: M5K 0A1 CORRESP 1 filename1.htm

Univest Securities LLC
75 Rockefeller Plaza, Suite 1838

New York, NY 10019

 

March 18, 2024

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

 

Attention: Tamika Sheppard

 

Re:Akanda Corp. (the “Company”)
  Registration Statement on Form F-1
  File No. 333-277182 (the “Registration Statement”)

 

Dear Ms. Sheppard: 

 

Reference is made to our letter, filed as correspondence via EDGAR on March 18, 2024, in which we, as representative of the underwriters of the Company’s proposed public offering, joined the Company’s request for acceleration of the effective date of the above-referenced Registration Statement for Monday, March 18, 2024, at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. The Company is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

 

  Very truly yours,
   
  As representative of the underwriters
       
  Univest Securities, LLC
       
  By: /s/ Brad Richmond
    Name: Brad Richmond
    Title: COO and Co-Head of Investment Banking

 

cc: Joseph E. Segilia, Esq., Sullivan & Worcester LLP